| Similar Articles |
|---|
 |
The Motley Fool
May 18, 2011
Sean Williams |
10 Mid Caps to Rule Them All The future of Jazz Pharmaceuticals' narcolepsy drug is so bright you may actually sleep better at night.   |
The Motley Fool
April 27, 2011
Brian D. Pacampara |
Jazz Pharmaceuticals Shares Plunged then Recovered: What You Need to Know Shares of drug maker Jazz Pharmaceuticals suddenly plummeted 30% this morning only to quickly recover the majority of that loss. |
The Motley Fool
January 5, 2012
David Williamson |
Dendreon Investors: Why Shares Are Soaring Tripling Provenge sales causes shares to soar 50%. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
December 16, 2011
Brian Orelli |
Dendreon 2011: Supply Constrained to Missed Guidance A year in review for the biotech. |
The Motley Fool
October 11, 2010
Brian Orelli |
FDA Rejection, but Still Jazzed Up Sometimes, biotechs are like that. |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works. |
The Motley Fool
November 23, 2011
Brian Orelli |
I Was Wrong About Dendreon But maybe not in the long term. |
The Motley Fool
August 4, 2011
Brian Orelli |
Dendreon Down 65%! What's Next? What caused Dendreon's shocking collapse? |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
August 10, 2011
Jim Mueller |
Rising Star Buy: Digging Dendreon After getting hammered, there's an opportunity here. |
The Motley Fool
May 10, 2006
Brian Lawler |
Dendreon Drives On Will the FDA say yes to a new cancer drug? Investors, take note. |
The Motley Fool
August 8, 2011
Luke Timmerman |
Dendreon Wounds Are Self-Inflicted, Not the Start of a Biotech Industry Virus Is Dendreon doomed? |
The Motley Fool
November 3, 2011
Brian Orelli |
Modest Growth, Less-Than-Modest Stock Drop Dendreon's investors aren't happy. |
Chemistry World
January 27, 2014
Jennifer Newton |
Jazz spending spree has ups and downs Jazz Pharmaceuticals has agreed with Aerial Bio Pharma to acquire the rights to ADX-N05, a drug designed to treat narcolepsy. |
The Motley Fool
July 22, 2011
Brian Orelli |
It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
April 14, 2009
Brian Orelli |
Sell Dendreon! No, Buy Dendreon! Dendreon, everyone's favorite tiny biotech, just got bigger because of positive phase 3 results for its prostate cancer treatment, Provenge. |
The Motley Fool
August 29, 2011
Brian Orelli |
We Can Make More! Too Bad Few Want It Dendreon is no longer constrained by its supply. |
The Motley Fool
November 13, 2009
Rich Duprey |
5 Stocks That Laugh at Wall Street These companies' earnings handily beat analyst forecasts: General Steel... Jazz Pharmaceuticals... MGM Mirage... Stillwater Mining... Penn West Energy... |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
June 22, 2009
Jim Mueller |
Dendreon: Cash Out or Keep Riding Up? Given Dendreon's rise this year and Provenge's prospects, what should a prudent investor do? |
The Motley Fool
March 25, 2011
Selena Maranjian |
Make Money in Pharmaceuticals the Easy Way There's no need to guess which pharmaceutical company will perform best with the SPDR S&P Pharmaceuticals ETF. |
The Motley Fool
December 28, 2007
Brian Orelli |
The Biggest Health-Care IPOs of 2007 Let's take a look at four of the most intriguing health care IPOs from 2007. |
The Motley Fool
September 3, 2011
Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Jazz Pharmaceuticals Jazz Pharmaceuticals seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
AskMen.com
Ryan McKee |
How To: Keep Up In A Jazz Conversation If you can hold your own and keep up in a jazz conversation, women will think you're deep, with art appreciation coursing through your veins. |
Smithsonian
November 2005
Tom Piazza |
35 Who Made a Difference: Wynton Marsalis In Katrina's aftermath, the trumpeter has rallied support for his native New Orleans. |
Pharmaceutical Executive
February 1, 2013
Julin et al. |
Fortuity and the First Amendment Caronia decision shows the staying power of Sorrell v. IMS Health. Don't bank just yet on putting your marketing muscle behind the safe and effective off-label uses of your FDA-approved drugs. |
